Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc.NVUS · Entity 6160 | President | March 19, 2020 | March 20, 2020 |
| Lexaria Bioscience Corp.LEXX · Entity 7641 | Director | August 12, 2024 | August 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eledon Pharmaceuticals, Inc.
Report date March 19, 2020 · Filed March 20, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.26 · Expires 2030-03-19 | Direct | 100,000 |
Reported balance
After 2020-03-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-19 · Grant · Acquired 100,000 · Balance 100,000 F1: This option represents a right to purchase a total of 100,000 shares of the Issuer's Common Stock, one quarter of which will become fully vested and exercisable on March 19, 2021, with the remaining 75,000 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 100,000 shares of the Issuer's Common Stock, one quarter of which will become fully vested and exercisable on March 19, 2021, with the remaining 75,000 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Lexaria Bioscience Corp.
Report date August 12, 2024 · Filed August 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common sharesSEC Table I · non-derivative | Direct | 3,100 |
Reported balance
After 2024-08-12 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2024-08-12 · Purchase · Acquired 1,600 · Balance 3,100 |
| common sharesSEC Table I · non-derivative | Direct | 1,500 |
Reported balance
Holding disclosure · report date 2024-08-12 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,500 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.04 · Expires 2027-09-02 | Direct | 3,400 |
Reported balance
Holding disclosure · report date 2024-08-12 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 3,400 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2027-10-12 | Direct | 5,000 |
Reported balance
Holding disclosure · report date 2024-08-12 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 5,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2028-07-25 | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2024-08-12 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 10,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.36 · Expires 2029-04-26 | Direct | 15,000 |
Reported balance
Holding disclosure · report date 2024-08-12 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 15,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.39 · Expires 2029-07-26 | Direct | 27,000 |
Reported balance
Holding disclosure · report date 2024-08-12 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 27,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2024 Filed Aug 13, 2024 14:55 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | Purchasecommon shares | 1,600 | $3.13 | $5,008.00 |
DisclosureSEC source: 0001855763-24-000013 · primary_doc.xml · nonDerivative · entry 2 TURKEL CATHERINE C. · CIK 0001705278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,100 Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 15:32 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 12,000 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001348362-24-000003 · primary_doc.xml · derivative · entry 6 TURKEL CATHERINE C. · CIK 0001705278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Shares · 12,000 shares Expires 2029-07-26 Read SEC document |
| April 26, 2024 Filed May 10, 2024 21:16 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 5,000 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001855763-24-000009 · primary_doc.xml · derivative · entry 5 TURKEL CATHERINE C. · CIK 0001705278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 5,000 shares Expires 2029-04-26 Read SEC document |
| July 25, 2023 Filed Jul 25, 2023 17:44 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 5,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001855763-23-000002 · primary_doc.xml · derivative · entry 4 TURKEL CATHERINE C. · CIK 0001705278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 5,000 shares Expires 2028-07-25 Read SEC document |
| February 09, 2023 Filed Feb 27, 2023 15:52 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | PurchaseCommon Shares | 1,500 | $2.84 | $4,266.90 |
DisclosureSEC source: 0001855763-23-000001 · primary_doc.xml · nonDerivative · entry 1 TURKEL CATHERINE C. · CIK 0001705278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Read SEC document |
| October 12, 2022 Filed Oct 13, 2022 21:16 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 1,600 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001855763-22-000015 · primary_doc.xml · derivative · entry 2 TURKEL CATHERINE C. · CIK 0001705278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Shares · 1,600 shares Expires 2027-10-12 Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 16:53 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 3,400 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001855763-22-000012 · primary_doc.xml · derivative · entry 1 TURKEL CATHERINE C. · CIK 0001705278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,400 Underlying: Common Shares · 3,400 shares Expires 2027-09-02 Read SEC document |
| March 19, 2020 Filed Mar 20, 2020 20:31 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0000899243-20-009125 · doc4.xml · derivative · entry 1 TURKEL CATHERINE C. · CIK 0001705278 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-03-19 F1 · derivative.exercise_date: This option represents a right to purchase a total of 100,000 shares of the Issuer's Common Stock, one quarter of which will become fully vested and exercisable on March 19, 2021, with the remaining 75,000 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| September 26, 2019 Filed Oct 1, 2019 01:30 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000899243-19-024432 · doc4.xml · derivative · entry 1 TURKEL CATHERINE C. · CIK 0001705278 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-09-26 F1 · derivative.exercise_date: This option represents a right to purchase a total of 75,000 shares of the Issuer's Common Stock, which will vest in equal installments on the first and second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| May 21, 2019 Filed May 22, 2019 20:12 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | SaleCommon Stock | 1,914 | $1.91 | $3,658.42 |
DisclosureSEC source: 0001562180-19-003055 · primarydocument.xml · nonDerivative · entry 2 TURKEL CATHERINE C. · CIK 0001705278 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,662 F1 · kind: Shares were sold to cover the reporting person's taxes due on the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $1.90 to $1.945. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 20, 2019 Filed May 22, 2019 20:12 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | SaleCommon Stock | 7,623 | $1.96 | $14,953.28 |
DisclosureSEC source: 0001562180-19-003055 · primarydocument.xml · nonDerivative · entry 1 TURKEL CATHERINE C. · CIK 0001705278 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,576 F1 · kind: Shares were sold to cover the reporting person's taxes due on the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.90 to $2.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 20:24 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0000899243-19-008141 · doc4.xml · derivative · entry 3 TURKEL CATHERINE C. · CIK 0001705278 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-03-14 F2 · derivative.exercise_date: This option represents a right to purchase a total of 50,000 shares of the Issuer's Common Stock, which will vest in equal quarterly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 20:24 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-008141 · doc4.xml · nonDerivative · entry 1 TURKEL CATHERINE C. · CIK 0001705278 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,199 F1 · price: This represents restricted stock units representing the right to receive shares of the Issuer's Common Stock, which will vest in full on the later of achievement of a performance-related goal or the first anniversary of the grant date. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 00:00 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | PurchaseCommon Stock | 16,632 | $5.02 | $83,476.01 |
DisclosureSEC source: 0000899243-18-024470 · doc4.xml · nonDerivative · entry 2 TURKEL CATHERINE C. · CIK 0001705278 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,199 F2 · price: This transaction was executed in multiple trades at prices ranging from $4.97 to $5.04. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 11, 2018 Filed Sep 14, 2018 00:00 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | PurchaseCommon Stock | 17,048 | $4.56 | $77,670.69 |
DisclosureSEC source: 0000899243-18-024470 · doc4.xml · nonDerivative · entry 1 TURKEL CATHERINE C. · CIK 0001705278 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,567 F1 · price: This transaction was executed in multiple trades at prices ranging from $4.47 to $4.70. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 05, 2018 Filed Sep 8, 2018 00:00 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | PurchaseCommon Stock | 805 | $3.97 | $3,192.63 |
DisclosureSEC source: 0000899243-18-024043 · doc4.xml · nonDerivative · entry 1 TURKEL CATHERINE C. · CIK 0001705278 · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse's IRA Disclosed balance after: 805 Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 22:46 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-18-007642 · doc4.xml · derivative · entry 2 TURKEL CATHERINE C. · CIK 0001705278 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2028-03-13 F2 · derivative.exercise_date: This option represents a right to purchase a total of 24,000 shares of the Issuer's Common Stock, one quarter of which will become fully vested and exercisable on March 13, 2019, with the remaining 18,000 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 22:46 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-007642 · doc4.xml · nonDerivative · entry 1 TURKEL CATHERINE C. · CIK 0001705278 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,519 F1 · price: This represents restricted stock units representing the right to receive shares of the Issuer's Common Stock, which will vest in full on the later of achievement of a performance-related goal or the first anniversary of the grant date. Read SEC document |
| November 06, 2017 Filed Nov 6, 2017 22:10 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0000899243-17-025437 · doc4.xml · derivative · entry 1 TURKEL CATHERINE C. · CIK 0001705278 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-11-06 F1 · derivative.exercise_date: This option represents a right to purchase a total of 50,000 shares of the Issuer's Common Stock one quarter of which will become fully vested and exercisable on 11/6/2018, with the remaining 37,500 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| May 24, 2017 Filed May 26, 2017 20:06 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 52,500 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000899243-17-014541 · doc4.xml · derivative · entry 1 TURKEL CATHERINE C. · CIK 0001705278 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2027-05-23 F1 · derivative.exercise_date: This option represents a right to purchase a total of 52,500 shares of the Issuer's Common Stock. 36,000 shares will vest ratably each month over three years beginning on May 24, 2017 (the "grant date"). 16,500 shares will vest on the later of achievement of a performance-related goal or the first anniversary of the grant date. Read SEC document |
| May 10, 2017 Filed May 12, 2017 00:33 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | PurchaseCommon Stock | 11,111 | $9.99 | $110,998.89 |
DisclosureSEC source: 0000899243-17-012934 · doc4.xml · nonDerivative · entry 1 TURKEL CATHERINE C. · CIK 0001705278 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,519 F1 · shares: All numbers give effect to the 1:9 reverse stock split effected by the Company on May 11, 2017. F1 · balance_after: All numbers give effect to the 1:9 reverse stock split effected by the Company on May 11, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.